Matthew Barton, MD
Internal Medicine · Lees Summit, MONPI 1720051121
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Viiv Healthcare Company accounts for 64.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $47 and has fallen 72.3% since, to $13 in 2021. That places this record below the midpoint for internal medicine clinicians in MO, where the typical reported total is $189.
Across 4 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$47
- Supernus Pharmaceuticals, Inc.$13
- Boston Scientific$13
Across 14 payments — averaging $13,882 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Noven Pharmaceuticals, Inc.$194K
What the payments were for
- Food & beverage$74100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
How this compares
$74 in reported general payments places this provider in the 35th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $208,152 |
| JardianceEmpagliflozin | 199 | $203,503 |
| EliquisApixaban | 132 | $132,049 |
| JanuviaSitagliptin Phosphate | 51 | $58,811 |
| XareltoRivaroxaban | 64 | $52,604 |
| Erythromycin Ethylsuccinate | 14 | $51,147 |
| TrulicityDulaglutide | 42 | $42,727 |
| Repatha SureclickEvolocumab | 37 | $36,464 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $31,605 |
| FarxigaDapagliflozin Propanediol | 28 | $26,533 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 70 | $20,281 |
| LinzessLinaclotide | 30 | $19,765 |
| MounjaroTirzepatide | 14 | $18,865 |
| MyrbetriqMirabegron | 17 | $16,949 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 63 | $15,860 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lees Summit
- Timothy SmithSaint Peters$428K
- Craig DietzKansas City$226K
- Kevin SuttmoellerKansas City$198K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.